
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol. , 13 June 2018
Sec. T Cell Biology
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.01343
This article is part of the Research Topic Understanding gamma delta T Cell Multifunctionality - Towards Immunotherapeutic Applications View all 27 articles
This article is a correction to:
Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
A corrigendum on
There is an error in the Funding statement. The correct name for one of the funders is Ministero della Salute. The correct Funding statement is: This work has been partially supported by grants from AIRC to AP (IG15483) and AIRC to MZ (IG17074) and from 5xmille 2012 Ministero della Salute, 5xmille 2013 Ministero della Salute, 5xmille 2014 Ministero della Salute, and 5xmille 2015 Ministero della Salute to AP. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: CRC, spheroid, γδ T cells, epidermal growth factor receptor, antibody-dependent cellular cytotoxicity, zoledronate
Citation: Varesano S, Zocchi MR and Poggi A (2018) Corrigendum: Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures. Front. Immunol. 9:1343. doi: 10.3389/fimmu.2018.01343
Received: 27 May 2018; Accepted: 30 May 2018;
Published: 13 June 2018
Edited by:
Frontiers in Immunology Editorial Office, Frontiers Media SA, SwitzerlandCopyright: © 2018 Varesano, Zocchi and Poggi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessandro Poggi, YWxlc3NhbmRyby5wb2dnaUBoc2FubWFydGluby5pdA==;
Maria Raffaella Zocchi, em9jY2hpLm1hcmlhQGhzci5pdA==
†These authors have contributed equally to this work.
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.